ELEVATE: Study design of the observational study of bimekizumab in adult patients with moderate to severe plaque psoriasis

被引：0
|
作者：
Asadullah, Khusru [1 ,2 ]
Stavermann, Thomas [3 ]
Heidbrede, Tanja [4 ]
Schlueter, Kathrin [5 ]
Fierens, Frederik [6 ]
Thaci, Diamant [7 ]
von Kiedrowski, Ralph Michael [8 ]
机构：
[1] Hautarztpraxis, Potsdam, Germany
[2] Hautklin Charite, Berlin, Germany
[3] MVZ Hautzentrum Gropiuspas GmbH, Berlin, Germany
[4] UCB BioSci GmbH, Monheim, Germany
[5] UCB Pharma GmbH, Monheim, Germany
[6] UCB Pharma srl, Brussels, Belgium
[7] Univ Klinikum Schleswig Holstein, Inst Entzundungsmed, Campus Lubeck, Lubeck, Germany
[8] CMS3 GmbH, Selters, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P116
引用
收藏
页码：81 / 82
页数：2
相关论文
共 50 条
  • [41] Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis
    Leonardi, C
    Goffe, B
    Sobell, J
    Caro, I
    Wang, X
    Papp, K
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (03) : A58 - A58
  • [42] The experience of pain and redness in patients with moderate to severe plaque psoriasis
    Martin, Mona L.
    Gordon, Kenneth
    Pinto, Lionel
    Bushnell, Donald M.
    Chau, Dina
    Viswanathan, Hema N.
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2015, 26 (05) : 401 - 405
  • [43] Assessment of Cardiovascular Risk in Patients With Moderate to Severe Plaque Psoriasis
    Fernandez-Llaca, Hector
    de la Cueva, Pablo
    Luelmo, Jesus
    Carlos Armario-Hita, Jose
    Luz Samaniego, M.
    Garcia-Calvo, Carmen
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2014, 13 (10) : 1240 - 1247
  • [44] PSYCHOMETRIC EVALUATION OF THE PSORIASIS SYMPTOMS SCALE IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
    Armstrong, A. W.
    Edson-Heredia, E.
    Naegeli, A. N.
    Sun, L.
    Zhu, B.
    Wyrwich, K. W.
    [J]. VALUE IN HEALTH, 2018, 21 : S241 - S242
  • [45] Effectiveness and safety of secukinumab in patients with moderate to severe plaque psoriasis
    Moron, R.
    Alvarez, R.
    Nieto, P.
    Garcia, C.
    Belda, S.
    Cabeza, J.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 378 - 378
  • [46] Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis
    Papp, KA
    Miller, B
    Gordon, KB
    Caro, I
    Kwon, P
    Compton, PG
    Leonardi, CL
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (04) : S164 - S170
  • [47] Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
    Timmermann, Stine
    Hall, Anders
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 125 (01) : 16 - 25
  • [48] Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis
    Dauden, E.
    Prieto-Perez, R.
    Llamas-Velasco, M.
    Cabaleiro, T.
    Abad-Santos, F.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S188 - S188
  • [49] Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
    Gordon, Kenneth B.
    Langley, Richard G.
    Warren, Richard B.
    Okubo, Yukari
    Gold, Linda Stein
    Merola, Joseph F.
    Peterson, Luke
    Wixted, Krista
    Cross, Nancy
    Deherder, Delphine
    Thaci, Diamant
    [J]. JAMA DERMATOLOGY, 2022, 158 (07) : 735 - 744
  • [50] Ocular manifestations in moderate-to-severe psoriasis in India: A prospective observational study
    Kharolia, Anjali
    Parija, Sucheta
    Moharana, Bruttendu
    Sirka, Chandra Sekhar
    Sahu, Sandip Kumar
    [J]. INDIAN JOURNAL OF OPHTHALMOLOGY, 2022, 70 (09) : 3328 - 3332
12345